Christian Angermayer: Disrupting Sports With PEDs | EP 21
Mar 6, 2024
auto_awesome
Venture capitalist Christian Angermayer discusses disrupting sports with performance-enhancing drugs, longevity companies reversing aging, and controversial topics like allowing PEDs in sports. The podcast explores his journey from academia to entrepreneurship, investing in psychedelics for mental health, and the pursuit of enhancing health span. It also touches on brain-computer interface technology, personal growth through failures, and the tradition of gifting gold to guests.
Advancements in longevity companies may lead to the reversal of aging, focusing on enhancing longevity.
Proposing an aesthetics competition model challenges traditional perceptions by endorsing performance enhancements.
Christian Angermayer's diverse entrepreneurial journey spans tutoring business to innovative ventures like psychedelics and crypto.
Psychedelics hold therapeutic promise for mental health, with companies like Compass Pathway prioritizing research and FDA approvals.
Deep dives
Advancements in Longevity Companies
Significant advancements in longevity companies like Cambria and Rejuvaron are leading to the potential reversal of aging in our lifetime. These companies are focused on providing people with more time by enhancing longevity.
Aesthetics Competition Model
Proposing an aesthetics competition model similar to the Olympics, where performance enhancements are not just allowed but endorsed, challenges traditional perceptions. The killer argument presented highlights the prevalence of doping in existing athletic competitions.
Entrepreneurial Journey and Business Expansion
Christian Agamire shares his journey from starting a tutoring business at 14 to entrepreneurial success. The expansion into psychedelic mushrooms, longevity, and crypto ventures reflects his innovative and diverse business approach.
Psychedelics and Therapeutic Benefits
Christian's journey into psychedelics, driven by personal and medical curiosities, underscores the potential therapeutic benefits of psychedelics. Initiatives like Compass Pathway and Atai prioritize scientific research, FDA approvals, and therapeutic applications of psychedelics for mental health issues.
Navigating Funding Challenges and Regulatory Landscape
The challenges of funding and regulatory approval processes in the psychedelic industry pose obstacles for companies like Compass and Atai. Despite fluctuations in stock prices and uncertainties around insurance coverage, these companies persist in advancing research and seeking approval for psychedelic therapies.
Psychedelics Revolutionizing Mental Health Treatment and Investment Strategy
Psychedelics are poised to revolutionize mental health treatment by changing how it is delivered, with a focus on owning IP and patents to enable substantial investment in the industry. Early entrants like Compass and Ty have strategically developed IP around psychedelics, positioning them as key players. Despite market fluctuations and initial hype, the industry, like biotech, faces challenges in perception and valuation, with a need to address key questions like insurer acceptance. However, the potential to solve mental health issues and enhance happiness underscores the undervalued nature of companies like a tie and Compass.
Exploring Longevity and Human Enhancement
Longevity is redefined as a process of extending healthy lifespan rather than merely reaching 500 years, emphasizing gradual improvements. Aging is no longer viewed as a singular disease but as the interplay of various identifiable factors, paving the way for targeted treatments and interventions. Human enhancement technologies, such as brain-computer interfaces, showcase the potential to address severe disabilities and unlock telepathic communication, aligning with broader goals of enhancing human abilities and longevity. Defining success amidst failures and navigating partnerships highlight the resilience required in entrepreneurship and personal growth, stressing the importance of seeking opportunities in adversity and perceiving life's challenges as transformative lessons.
A visionary financier with a mission to reverse aging and change perceptions about commonly misunderstood drugs. Christian and Mike first joined forces in 2017 to invest in the groundbreaking field of psychedelics. He ran a successful tutoring business that set him on the path to financial success to the daring ventures that catapulted him into the billionaire's club, Christian shares his journey and insights. Discover how he merges his passion for biotech innovation with savvy investment strategies to transform emerging concepts into impactful businesses. A man who combines a deep understanding of science with financial acumen, reshaping industries and influencing future technologies.
Neither the information, nor any opinion contained in this podcast, constitutes an offer to buy or sell, or a solicitation of an offer to buy or sell securities or other financial instruments or to participate in any advisory services or trading strategy. Nothing contained in this document constitutes investment, legal or tax advice or is an endorsement of any of the investments/companies mentioned herein.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
